Jefferies analyst Raj Denhoy raised his estimates for Teleflex (TFX) and Boston Scientific (BSX) after conducting a survey of 50 U.S.-based urologists to better understand demand and utilization trends for Teleflex's recently acquired UroLift and Boston Scientific's recently acquired Rezum System. He found that UroLift is 15% of procedure mix and expected to reach 25% in two years, and that current mix for Rezum is 10% and expected to be 20% in two years. UroLift taking share from all other modalities including drug therapy while Rezum is gaining share from surgery/ablation, Denhoy tells investors in a research note. The analyst increased his price target for Teleflex to $300 and for Boston Scientific to $45. He keeps Buy rating on both stocks.

RBC Capital raised the firm's price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company's Q1 momentum on seales and earnings, along with its new product ramp, the management's updated FY24 guidance is likely "conservative" despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its "industry-leading growth profile".

Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."

Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.

Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here